Lupin net jumps 42% to Rs 335 crore
Shares of Lupin were trading at Rs 608.15 apiece on the BSE in late afternoon trade, up 1.49 per cent from their previous close.
By ET Bureau | Updated:
MUMBAI: The country's fifth-largest pharmaceutical company Lupin has reported a 42.5% jump in net profit to Rs 335.2 crore in the quarter to December, beating street expectations.
The company said consolidated revenue grew 37.5% over the year-ago quarter to Rs 2,501 crore, while earnings before interest, tax, depreciation and amortisation (Ebitda) rose 62% to Rs 605 crore.
US formulations, which contributed over 40% of the total revenue, reported sales of Rs 1,039 crore, registering an increase of 68%. The India formulations business contributed 23% of the total revenue at Rs 570 crore. I'rom Pharmaceutical, which Lupin acquired through its Japanese subsidiary Kyowa, reported a 48% rise in net sales to Rs 365 crore.
The company said consolidated revenue grew 37.5% over the year-ago quarter to Rs 2,501 crore, while earnings before interest, tax, depreciation and amortisation (Ebitda) rose 62% to Rs 605 crore.
US formulations, which contributed over 40% of the total revenue, reported sales of Rs 1,039 crore, registering an increase of 68%. The India formulations business contributed 23% of the total revenue at Rs 570 crore. I'rom Pharmaceutical, which Lupin acquired through its Japanese subsidiary Kyowa, reported a 48% rise in net sales to Rs 365 crore.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
